Natera, Inc. (NTRA)

NMS – Real vaqt narxi. Valyuta: USD

314.38

+1.66 (0.53%)

Bozor ochiq: Aug 12, 2026, 3:27 PM EDT

314.00

+1.28 (0.41%)

Oldingi bozordan keyin: Aug 11, 2026, 7:52 PM EDT

12.08.2026

Natera to Support New Clinical Trial Assessing ctDNA Dynamics with Latitude™ in Advanced Skin Cancers

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a new collaboration regarding a Phase 1 clinical trial, sponsored by Kupando Therapeutics. Under the agreement, Natera's Latitude tissue-free assay for molecular residual disease (MRD) detection will be used in Kupando's clinical trial of its lead immunotherapy candidate, KUP-101. The trial will assess serial circulating tumor DNA (ctDNA) dynamics as part of trea.

07.08.2026

Natera Shares Soar Over 20% To All-Time High, Bolstering Co-Founder's Billionaire Status

40.6%. That is how much Natera shares have grown since the start of the year, when they were priced around the $228 mark. The company's lowest closing price this year occurred in late March, when shares fell to $182.65.

07.08.2026

Natera Q2 Earnings Call Highlights

Natera NASDAQ: NTRA reported second-quarter 2026 revenue of approximately $753 million, up about 38% from a year earlier, as record testing volumes and higher average selling prices supported growth across its oncology, women's health and organ health businesses.

07.08.2026

Natera (NTRA) Reports Q2 Loss, Beats Revenue Estimates

Natera (NTRA) came out with a quarterly loss of $0.47 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.74 per share a year ago.

06.08.2026

Natera, Inc. (NTRA) Q2 2026 Earnings Call Transcript

06.08.2026

Natera Reports Second Quarter 2026 Financial Results

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the second quarter ended June 30, 2026. Recent Financial Highlights Generated total revenues of $752.8 million in the second quarter of 2026, compared to $546.6 million in the second quarter of 2025, an increase of 37.7%. Generated a gross margin1 of 64.5% in the second quarter of 2026, compared to a gross margin1 of 63.4% in the second quar.

06.08.2026

Natera Eyes Massive New Cancer Market; In Buy Zone With Q2 Report Due

Colon cancer test provider Natera is in a buy zone above a cup base ahead of second-quarter results due Thursday.

Videolar

No Data

There is no data to display

Press-relizlar

12.08.2026

Natera to Support New Clinical Trial Assessing ctDNA Dynamics with Latitude™ in Advanced Skin Cancers

06.08.2026

Natera Reports Second Quarter 2026 Financial Results

05.08.2026

Natera Submits Signatera™ to Japan's PMDA for Approval as a Companion Diagnostic in Muscle-Invasive Bladder Cancer

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it has submitted an application to Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for approval of the Signatera test in muscle-invasive bladder cancer (MIBC) as a companion diagnostic (CDx). The submission advances Natera's growing presence in Japan, where Signatera received PMDA approval in colorectal cancer in June, becoming the country's first.

Natera, Inc. (NTRA)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Natera, Inc. (NTRA)

Natera to Support New Clinical Trial Assessing ctDNA Dynamics with Latitude™ in Advanced Skin Cancers

Natera Shares Soar Over 20% To All-Time High, Bolstering Co-Founder's Billionaire Status

Natera Q2 Earnings Call Highlights

Natera (NTRA) Reports Q2 Loss, Beats Revenue Estimates

Natera, Inc. (NTRA) Q2 2026 Earnings Call Transcript

Natera Reports Second Quarter 2026 Financial Results

Natera Eyes Massive New Cancer Market; In Buy Zone With Q2 Report Due

Videolar

No Data

Press-relizlar

Natera to Support New Clinical Trial Assessing ctDNA Dynamics with Latitude™ in Advanced Skin Cancers

Natera Reports Second Quarter 2026 Financial Results

Natera Submits Signatera™ to Japan's PMDA for Approval as a Companion Diagnostic in Muscle-Invasive Bladder Cancer

Natera to Support New Clinical Trial Assessing ctDNA Dynamics with Latitude™ in Advanced Skin Cancers

Natera Shares Soar Over 20% To All-Time High, Bolstering Co-Founder's Billionaire Status

Natera Q2 Earnings Call Highlights

Natera (NTRA) Reports Q2 Loss, Beats Revenue Estimates

Natera, Inc. (NTRA) Q2 2026 Earnings Call Transcript

Natera Reports Second Quarter 2026 Financial Results

Natera Eyes Massive New Cancer Market; In Buy Zone With Q2 Report Due

Videolar

No Data

Press-relizlar

Natera to Support New Clinical Trial Assessing ctDNA Dynamics with Latitude™ in Advanced Skin Cancers

Natera Reports Second Quarter 2026 Financial Results

Natera Submits Signatera™ to Japan's PMDA for Approval as a Companion Diagnostic in Muscle-Invasive Bladder Cancer

Search stocks

Natera, Inc. (NTRA)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Natera, Inc. (NTRA)

Natera to Support New Clinical Trial Assessing ctDNA Dynamics with Latitude™ in Advanced Skin Cancers

Natera Shares Soar Over 20% To All-Time High, Bolstering Co-Founder's Billionaire Status

Natera Q2 Earnings Call Highlights

Natera (NTRA) Reports Q2 Loss, Beats Revenue Estimates

Natera, Inc. (NTRA) Q2 2026 Earnings Call Transcript

Natera Reports Second Quarter 2026 Financial Results

Natera Eyes Massive New Cancer Market; In Buy Zone With Q2 Report Due

Videolar

No Data

Press-relizlar

Natera to Support New Clinical Trial Assessing ctDNA Dynamics with Latitude™ in Advanced Skin Cancers

Natera Reports Second Quarter 2026 Financial Results

Natera Submits Signatera™ to Japan's PMDA for Approval as a Companion Diagnostic in Muscle-Invasive Bladder Cancer

Natera to Support New Clinical Trial Assessing ctDNA Dynamics with Latitude™ in Advanced Skin Cancers

Natera Shares Soar Over 20% To All-Time High, Bolstering Co-Founder's Billionaire Status

Natera Q2 Earnings Call Highlights

Natera (NTRA) Reports Q2 Loss, Beats Revenue Estimates

Natera, Inc. (NTRA) Q2 2026 Earnings Call Transcript

Natera Reports Second Quarter 2026 Financial Results

Natera Eyes Massive New Cancer Market; In Buy Zone With Q2 Report Due

Videolar

No Data

Press-relizlar

Natera to Support New Clinical Trial Assessing ctDNA Dynamics with Latitude™ in Advanced Skin Cancers

Natera Reports Second Quarter 2026 Financial Results

Natera Submits Signatera™ to Japan's PMDA for Approval as a Companion Diagnostic in Muscle-Invasive Bladder Cancer